Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPK14 | Q16539 | 5/20 | 0.53 |
| ▸ | MAPK13 | O15264 | 4/20 | 0.53 |
| ▸ | MAPK12 | P53778 | 4/20 | 0.53 |
| ▸ | MAPK11 | Q15759 | 4/20 | 0.53 |
| ▸ | EGFR | P00533 | 1/20 | 0.50 |
| ▸ | MET | P08581 | 1/20 | 0.50 |
| ▸ | TP53 | P04637 | 1/20 | 0.43 |
| ▸ | MAPT | P10636 | 5/20 | 0.43 |
| ▸ | NPC1 | O15118 | 1/20 | 0.43 |
| ▸ | RAB9A | P51151 | 1/20 | 0.43 |
| ▸ | IDO1 | P14902 | 1/20 | 0.43 |
| ▸ | TDO2 | P48775 | 1/20 | 0.43 |
| ▸ | POLB | P06746 | 1/20 | 0.43 |
| ▸ | GAA | P10253 | 1/20 | 0.43 |
| ▸ | RECQL | P46063 | 1/20 | 0.43 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | GFER | P55789 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.42 |
| ▸ | PDGFRA | P16234 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL2203119 | 0.87 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL2199213 | 0.87 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL2199146 | 0.87 | MAPK14 (0.54) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL2199595 | 0.86 | PYGL (0.53) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL2863941 | 0.85 | MAPK14 (0.57) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL5752508 | 0.85 | EGFR (0.66) | MAPK14EGFRMETMAPTNPC1 | |
| SCHEMBL2866402 | 0.83 | MAPK14 (0.56) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL2199336 | 0.83 | MAPK14 (0.48) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL2198633 | 0.81 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11EGFR | |
| SCHEMBL2196670 | 0.81 | MAPK14 (0.51) | MAPK14MAPK13MAPK12MAPK11EGFR |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8293772-B2 | Triazole substituted aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2012-10-23 | — | — | US | disclosed |
| EP-1828148-B1 | TRIAZOLE SUBSTITUTED AMINOBENZOPHENONE COMPOUNDS | LEO PHARMA AS (DK) | 2010-01-20 | — | — | EP | disclosed |
| US-20060128766-A1 | Triazole substituted aminobenzophenone compounds | LEO PHARMA A/S (DK) | 2006-06-15 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060128766-A1 | Triazole substituted aminobenzophenone compounds | NFKBIA, UACA, CYP1B1 | MAPK14 1089/4885MAPK13 1436/4885MAPK12 1829/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.